Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study

International Journal of Cancer

Volumn 65, Issue 4, 1996, Pages 442-445

  Sakaguchi, Masahiro ^a   Fujii, Yoshitaka ^a   Hirabayashi, Hirohisa ^a   Yoon, Hyung Eun ^a   Komoto, Yosuke ^a   Oue, Takaharu ^a   Kusafuka, Takeshi ^a   Okada, Akira ^a   Matsuda, Hikaru ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN;

ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; RETINOBLASTOMA PROTEIN;

EID: 0029971843     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X     Document Type: Article

References (22)

1. CAIRNS, P., MAO, L., MERLO, A., LEE, D., SCHWAB, D., EBY, Y., TOKINO, K., VAN DER RIET, P., BLAUGRUND, J. and SIDRANSKY, D., Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-416 (1994).
2. CALDAS, C., HAHN, S.A., DA COSTA, L.T., REDSTON, M.S., SCHUTTE, M., SEYMOUR, A.B., WEINSTEIN, C.R., HRUBAN, R.H., YEO, C.J. and KERN, S.-E., Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature (Genet ). 8, 27-32 (1994).
3. CHENG, J.Q., JHANWAR, S.C., KLEIN, W.M., BELL, D.W., LEE, WENCHING, ALTOMARE, D.A., NOBORI, T., OLOPADE, O.I., BUCKLER, A.J. and TESTA. J.R., p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res., 54, 5547-5551 (1994).
4. JEN, J., HARPER, W., BIGNER, S.H., PAPADOPOULOS, N., MARKOWITZ, S.. WILSON, J.K.V., KINZLER, K.W. and VOGELSTEIN, B., Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54, 6353-6358 (1994).
5. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., LIU, Q., HARSHMAN, K., TAVTIGAN, S.V., STOCKERT, E., DAY, R.S., III, JOHNSON, B.E. and SKOLNICK, M.H., A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
6. KATO, J.Y., MATSUSHUME, H., HIEBERT, S.W., EWEN, M.E. and SHERR, C.J., Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Develop., 7, 331-342 (1993).
7. LI, Y., NICHOLS, M.A., SHAY, J.W. and XIONG, Y., Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54, 6078-6082 (1994).
8. MERLO, A., HERMAN, J.G., MAO, L., LEE, D.J., GABRIELSON, E., BURGER, P.C., BAYLIN, S.B. and SIDZAVSKY, D., 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor CDKN2/p16 in human cancers. Nature (Med.), 7, 686-692 (1995).
9. MORI, T., MIURA, K., AOKI, T., NISHIHIRA, T., MORI, S. and NAKAMURA, Y., Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397 (1994).
10. NOBORI, T., MIURA, K., Wu, D.J., Lois, A., TAKABAYASHI, K. and CARSON, D.A., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368, 753-756 (1994).
11. INK4 in human cancer. Proc. nat. Acad. Sci. (Wash.), 91, 11045-11049 (1994).
12. INK4 protein induction by 5-aza 2′ deoxvcytidine. Oncogene, 11, 1211-1216 (1995).
13. INK4 protein is restricted to be subset of lung cancer lines that retains wild-type RB. Oncogene, 9, 3375-3378 (1994).
14. INK4 / MTSI suppressor gene product. EMBO J., 14, 503-511 (1995).
15. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D / CDK4. Nature (Lond.), 366, 704-707 (1993).
16. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55, 505-509 (1995).
17. 1 cyclins. Cell, 79, 551-555 (1994).
18. SHIMIZU, E., COXON, A., OTTERSON, G.A., STEINBERG, S.M., KRATZKE, R.A., KIM, Y.W., FEDORKO, J., OIE, H., JOHNSON, B.E., MULSHINE, J.L., MINNA, J.D., GAZDAR, A.F. and KAYE, F.J., RB protein status and clinical correlation from 171 cell lines representing lung cancer. extrapulmonary small cell carcinoma, and mesothelioma. Oncogene, 9, 2441-2448 (1994).
19. Ink4. Cancer Res., 54, 5816-5820 (1994).
20. WASHIMI, O., NAGATAKE, M., OSADA, H., UEDA, R., KOSHIKAWA, T., SEKI, T., TAKAHASHI, T. and TAKAHASHI, T., In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res., 55, 514-517 (1995).
21. YEAGER, T., STADLER, W., BELAIR, C., PUTHENVEETTIL, J., OLOPADE, O. and REZNIKOFF, C., Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55, 493-497 (1995).
22. ZHANG, SHI-YU, KLEIN-SZANTO, AJ.P., SAUTER, E.R., SHAFARENKO, M., MITSUNAGA, S., NOBORI, T., CARSON, D.A., RIDGE, J.A. and GOODROW, T.L., Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54,5050-5053 (1994).